CTRI/2013/10/004104已完成4 期
Open label, Multicenter, prospective study to evaluate the efficacy and safety of Capixyl lotion (5%) in subjects with MPHL (Male Pattern Hair Loss)
Glenmark Pharmaceuticals Ltd0 个研究点目标入组 44 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1.Healthy volunteers suffering from MPHL (18-45 yrs).
- •2.For Male volunteers MPHL of grade II-IV (Norwood classification)
- •3.As per the Trichoscopy report, -Anisotrichosis >20%
- •4.Subjects must comply with the protocol.
排除标准
- •1.Non pattern hair loss
- •2.Thyroid related conditions
- •3.Other possible pathologies contributing to hair loss
- •4.Patient on Ketoconazole /Topical minoxidil / Finasteride or any other hair growth therapy
- •5.Not able to comply to protocol
研究者
相似试验
进行中（未招募）
不适用
Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent &#946;-thalassemic patients with cardiac MRI T2* <20 msec - NDcardiac iron overloadMedDRA version: 9.1Level: LLTClassification code 10019024Term: HaemosiderosisEUCTR2008-003230-22-ITOVARTIS FARMA
进行中（未招募）
1 期
Prospective, multicenter, open-label study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus, and cardiotoxic treatments (CIBER-bB-ECHO).Patients with cardiovascular alterations induced by cirrhosis, diabetes mellitus and cardiotoxic treatments.CTIS2024-514880-25-00Consorcio Centro De Investigacion Biomedica En Red1,000
进行中（未招募）
1 期
Clinical trial to evaluate the safety and efficacy of intravitreal ranibizumab in patients with choroidal neovascularization secondary to other causes than Age-related Macular Degeneration and Pathological Myopia.Patients with subfoveal or juxtafoveal choroidal neovascularization secondary to other causes than Age-related Macular Degeneration and Pathological Myopia (angioid streaks, pseudohistoplasmosis, inflammatory chorioretinal diseases and idiopathic lesions).MedDRA version: 13.1Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 10015919 - Eye disordersEUCTR2009-014612-34-PTAIBILI - Association for Innovation and Biomedical Research on Light and Image20
进行中（未招募）
1 期
Multicentre, open-label study to investigate the effects Cufence has, the effects the body has on Cufence and the continued safety and efficacy on patients with Wilson DiseaseWilson DiseaseMedDRA version: 22.1Level: PTClassification code 10019819Term: Hepato-lenticular degenerationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004604-33-PLnivar Solutions, B.V.50
进行中（未招募）
1 期
Multicentre, open-label study to investigate the effects Cufence has, the effects the body has on Cufence and the continued safety and efficacy on patients with Wilson DiseaseEUCTR2020-004604-33-FRnivar Solutions, B.V.50